24 APAC / Issue Q2 2020 , Antengene Corporation appoints former Celgene ANZ general manager Thomas Karalis as Head of Asia Pacific Regions. Antengene Corporation recently announced the appointment of Mr. Thomas Karalis as Head of Asia Pacific Regions. In this position, Tom will be responsible for the commercialisation of Antengene products in Australia, New Zealand, S. Korea, Taiwan, Hong Kong and ASEAN regions and will report directly to Mr. John Chin, Chief Business Officer of Antengene. Tom is a seasoned industry leader with over 30 years of experience working at several multinational biopharmaceutical companies in Australia and across multiple Asia Pacific countries/regions. Equipped with exceptional commercial leadership and strategic thinking, Tom has effectively initiated numerous critical initiatives in geographic expansion, enterprise design and portfolio transformation. Before joining Antengene, he was the General Manager for Celgene East Asia and Vice President & General Manager for Celgene Australia and New Zealand, where he made outstanding accomplishments in general management and commercial strategies. Tom spent eight years at Celgene, during which multiple regulatory and reimbursement milestones were achieved for core products in APAC markets leading to successful launches of REVLIMID® (lenalidomide), POMALYST® (pomalidomide) and ABRAXANE® (paclitaxel protein-bound particles for injectable suspension). Prior to Celgene, he served as General Manager for Abbott Nutrition (Philippines), BMS (Thailand, Vietnam, Singapore), and held Seasoned Industry Leader senior positions at Eli Lilly (South Korea) and Pharmacia. “Today, Antengene is at critical stage to accelerate its growth in Asia pacific market. Our vision is to treat patients beyond boarders, which drives us to meet the unmet medical needs by bringing innovative therapies to cancer patients in the region and worldwide,” said Dr. Jay Mei, Chairman and CEO of Antengene. “We are glad that Tom is joining the Antengene team and with his proven successful track record as a Commercial Leader, Tom will further strengthen our ability to deliver meaningful results and grow our footprint in Australia and the other countries/regions now and into the future. “ “As we prepare to launch ATG- 010 (selinexor) in China, we also continue to seek global opportunities to expand our presence and commercialisation of our future pipeline.” said John Chin, Chief Business Officer of Antengene, “I am confident that Tom, a seasoned industry leader with a proven track record, will accelerate the growth of a world-class commercial team for Antengene and bring value to cancer patients across the region.” “I am delighted to be joining Antengene at this exciting time. Dr. Jay Mei has built an impressive company with a talented team that is rapidly developing an innovative portfolio of cancer therapies. I am looking forward to working with Jay, John and the entire Antengene team to commercialise our portfolio and fulfil our mission of treating patients beyond borders as we build an industry leading cancer company.” said Mr. Thomas Karalis.